NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company developing a pipeline of selective oral immunology
therapies aimed at treating chronic inflammatory and autoimmune
diseases, today announced participation in the following
scientific, investor and industry conferences in April:
- April 17-22: 2021 Virtual
American Academy of Neurology (AAN) Annual Meeting.
Robert J. Fox, M.D., Staff
Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for
Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present the full data
set from Immunic's phase 2 EMPhASIS trial of its lead asset,
IMU-838, in patients with relapsing-remitting multiple sclerosis at
the 2021 Virtual AAN Annual Meeting.
-
- Abstract Number: 2872
- Title: Efficacy and Safety of the Selective Oral DHODH
Modulator Vidofludimus Calcium (IMU–838) in Relapsing-Remitting
Multiple Sclerosis: A Randomized, Placebo-Controlled Phase 2 Trial
(EMPhASIS)
- Session Title: P15: MS Clinical Trials and Therapeutics
- Program Number: P15.085
The poster presentation, including
an audio track, will be available in the virtual poster hall the
entire length of the meeting and for thirty days after the
conference. The poster will also be accessible on the "Events and
Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations. In addition, Dr. Fox will be
available for a virtual one-on-one discussion to address any
questions regarding the poster on Monday,
April 19, from 12:30 to 1:00 pm
ET via the conference portal.
- April 28-29: Virtual B.
Riley Neuroscience Conference. Daniel
Vitt, Ph.D., Chief Executive Officer and President of
Immunic, will participate in a fireside chat on Wednesday, April 28, at 9:30 am ET. Specific details regarding webcast
and replay information will be published on the "Events and
Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations, once they are available.
- April 28-30: German Corona
Showcase 2021 (held in English). Dr. Vitt will present an
overview of Immunic's phase 2 CALVID-1 trial of IMU-838 in moderate
COVID-19 on Friday, April 30, at
10:50 am CET (4:50 am ET). Specific details regarding webcast
and replay information will be published on the "Events and
Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations, once they are available.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company with a pipeline of
selective oral immunology therapies aimed at treating chronic
inflammatory and autoimmune diseases. The company is developing
three small molecule products: its lead development program,
IMU-838, a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH and exhibits a host-based antiviral effect, is
currently being developed as a treatment option for multiple
sclerosis, ulcerative colitis, Crohn's disease, COVID-19, and
primary sclerosing cholangitis. IMU-935, a selective inverse
agonist of the transcription factor RORγt, is targeted for
development in psoriasis and Guillain-Barré syndrome. IMU-856,
which targets the restoration of the intestinal barrier function,
is targeted for development in diseases involving bowel barrier
dysfunction. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's participation in scientific, investor and industry
conferences. Immunic may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Such statements are
based on management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient resources to meet business objectives
and operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by
Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be
found in the section captioned "Risk Factors," in the company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on
February 26, 2021, and in the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this
release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic expressly
disclaims all liability in respect to actions taken or not taken
based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-scientific-investor-and-industry-conferences-in-april-301266831.html
SOURCE Immunic, Inc.